Effects of (-)-epigallocatechin-3-gallate on EGFR- or Fusion Gene-driven Lung Cancer Cells

Acta Med Okayama. 2017 Dec;71(6):505-512. doi: 10.18926/AMO/55587.
No abstract available

Keywords: ALK; EGFR; ROS1; epigallocatechin-3-gallate; lung cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Animals
  • Blood Proteins / antagonists & inhibitors
  • Blotting, Western
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Catechin / analogs & derivatives*
  • Catechin / genetics
  • Catechin / pharmacology
  • Cell Line, Tumor
  • Crizotinib
  • Disease Models, Animal
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics
  • Female
  • Gene Rearrangement / drug effects*
  • Gene Rearrangement / genetics
  • Heterografts
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Mutation / genetics
  • Oncogene Proteins, Fusion / analysis
  • Oncogene Proteins, Fusion / genetics
  • Polyphenols / chemistry
  • Protein S
  • Protein-Tyrosine Kinases / administration & dosage
  • Pyrazoles / administration & dosage
  • Pyridines / administration & dosage
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • Tea / chemistry

Substances

  • Blood Proteins
  • Oncogene Proteins, Fusion
  • PROS1 protein, human
  • Polyphenols
  • Protein S
  • Pyrazoles
  • Pyridines
  • Tea
  • Crizotinib
  • Catechin
  • epigallocatechin gallate
  • ALK protein, human
  • Alk protein, mouse
  • Anaplastic Lymphoma Kinase
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Receptor Protein-Tyrosine Kinases